In the current study, we evaluated the diagnostic power of 18F-FDG-PET and its relationship to other commonly used AD biomarkers, including CSF Aβ42, t-tau, and p-tau as well as amyloid- and tau-PET results and cognition measures, using data from the ADNI cohort. The gene discussed is MAPT; the disease is Alzheimer disease.